Please login to the form below

Not currently logged in
Email:
Password:

PD-L1

This page shows the latest PD-L1 news and features for those working in and with pharma, biotech and healthcare.

EU approval for Opdivo combo in renal cell cancer

EU approval for Opdivo combo in renal cell cancer

a 37% decreased risk of death in intermediate- and poor-risk patients compared to a Sutent, observed regardless of PD-L1 expression level. ... category with its IMmotion 151 study comparing PD-L1 inhibitor Tecentriq plus Avastin to Sutent, which

Latest news

  • Chinese biotechs aim PD-L1 antibody at hepatitis B Chinese biotechs aim PD-L1 antibody at hepatitis B

    Suzhou Alphamab is already testing its PD-L1 inhibitor antibody KN035 in a number of clinical trials across tumour types in the US, China and Japan, but has licensed rights for ... Blocking the PD-1/PD-L1 pathway could be an effective immunotherapy

  • Nektar confirms BMS deal for NKTR-214 is on track Nektar confirms BMS deal for NKTR-214 is on track

    Nektar disclosed data from the PIVOT trial of NKTR-214 plus BMS’ PD-1 inhibitor Opdivo (nivolumab) at the ASCO meeting last year, although the two companies were forced to defend ... He also revealed that Nektar has agreed to test NKTR-214 with

  • AstraZeneca unveils reorg, hires controversial José Baselga as cancer chief AstraZeneca unveils reorg, hires controversial José Baselga as cancer chief

    This really is a dream job.”. Three new oncology drugs are already driving growth at AZ, namely targeted lung cancer drug Tagrisso (osimertinib) and ovarian cancer treatment Lynparza (olaparib) plus ... L1 immunotherapy Imfinzi (durvalumab), and the

  • AZ still sees route to approval for Imfinzi in MYSTIC trial AZ still sees route to approval for Imfinzi in MYSTIC trial

    AZ’s study looked specifically at patients whose tumours express PD-L1 on 25% or more of their cancer cells, and AZ says it is now important to explore the relative ... roles of PD-L1 expression and TMB in determining the efficacy of immunotherapy.

  • GSK buys cancer firm Tesaro for $5.1bn GSK buys cancer firm Tesaro for $5.1bn

    They point to the potential of pipeline candidates such as PD-1 inhibitor TSR-042, due to be filed for approval in recurrent endometrial cancer next year, which could give GSK ... The phase 2 JASPER trial, for example, pairs Zejula with TSR-042 in

More from news
Approximately 11 fully matching, plus 191 partially matching documents found.

Latest Intelligence

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    olaparib) plus biologic PD-L1 immunotherapy Imfinzi (durvalumab). ... patients with higher levels of PD-L1 expression in their tumours.

  • Combined immunotherapies – potential and pitfalls Combined immunotherapies – potential and pitfalls

    We hope to capitalise further on the effects of single agent anti-PD-1/PD-L1 and anti-CTLA-4 monotherapy trials and see even greater survival benefits for patients.”. ... There are a variety of strategies attempting to overcome intrinsic resistance to

  • The good, the bad and the ugly The good, the bad and the ugly

    Companies are looking to pair their PD-1/PD-L1 checkpoint inhibitors with a variety of other agents to stimulate a more robust anticancer immune response,” says Xuan.

  • European venture funding for the life science sector European venture funding for the life science sector

    is likely to accelerate interest - the sheer number of combination therapies and PD-1/PD-L1 inhibitors could result in a commoditisation of this area that could threaten returns for venture

  • The new launch paradigm The new launch paradigm

    Thousands of patients worldwide are in clinical trials with anti-PD-1 or anti-PD-L1 drugs produced by several pharmaceutical companies prior to the expected arrival of this new exciting

More from intelligence
Approximately 0 fully matching, plus 13 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics